HBM Holdings Limited (FRA:6XY)

Market Cap	1.07B +384.6%
Revenue (ttm)	98.53M +60.3%
Net Income	62.22M +243.1%
EPS	0.08 +221.3%
Shares Out	n/a
PE Ratio	17.23
Forward PE	15.34
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	161
Open	1.230
Previous Close	1.190
Day's Range	1.230 - 1.230
52-Week Range	0.396 - 2.140
Beta	n/a
RSI	37.92
Earnings Date	Nov 27, 2025

About HBM Holdings

HBM Holdings Limited, a biopharmaceutical company, engages in the discovery, development, and commercialization of antibody therapeutics focusing on immunology and oncology in Mainland China, the United States, Europe, and internationally. It develops the Harbour Mice Platform, which generates human monoclonal antibodies in two heavy and two light chain H2L2 and heavy chain formats. The company is developing Batoclimab (HBM9161), a human monoclonal antibody that selectively binds and inhibits the neonatal fragment crystallizable receptor for tr...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2016
• Employees: 210
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6XY

Financial Performance

In 2024, HBM Holdings's revenue was $38.10 million, a decrease of -57.43% compared to the previous year's $89.50 million. Earnings were $2.78 million, a decrease of -87.81%.

Financial numbers in USD